GlassScriptPhysician profile
Sharon R Burnside
NPI 1043231319
$16,350.95
in general payments reported to CMS, 2019-2025
34 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $2,091 · 2021: $2,355 · 2022: $2,349 · 2023: $2,633 · 2024: $2,307 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,280.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,271.48 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,744.28 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,473.81 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,399.26 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $1,074.44 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,036.29 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,022.50 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $858.88 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $790.19 | 2022-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $695.87 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $691.02 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $675.73 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $502.94 | 2019-2025 | Spravato |
| Tris Pharma INC | $353.68 | 2022-2025 | Dyanavel Xr |
| Allergan, INC. | $263.81 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $219.73 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $215.13 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $194.52 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $132.92 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Ironshore Pharmaceuticals INC. | $116.84 | 2019-2020 | |
| Eisai INC. | $111.81 | 2020-2021 | |
| Adlon Therapeutics L.P. | $101.37 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $68.33 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $64.76 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.40 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $41.03 | 2022-2023 | Belsomra |
| Azurity Pharmaceuticals, INC. | $40.84 | 2023 | Horizant |
| Neuronetics, INC. | $29.28 | 2019 | |
| Noven Therapeutics, LLC | $20.00 | 2024 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $17.30 | 2021 | |
| Boston Scientific Corporation | $16.95 | 2024 | Spaceoar Vue System - 10ml |
| Rhodes Pharmaceuticals L.P. | $16.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.70 | 2019 | |
| Shire North American Group INC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Burnside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.